

1 **Novel prognostic determinants of COVID-19-related mortality: a pilot study on**
2 **severely-ill patients in Russia**

3
4 **Rubina K.^{4*}, Shmakova A.¹, Shabanov A.³, Andreev Yu.³, Borovkova N.³, Kulabukhov**
5 **V.³, Evseev A.³, Popugaev K.³, Petrikov S.³, Semina E.^{1,2}**

6 ¹Laboratory of Molecular Endocrinology, Institute of Experimental Cardiology, Federal
7 State Budgetary Organization National Cardiology Research Center Ministry of Health of the
8 Russian Federation, Moscow, Russia

9 ²Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Lomonosov
10 Moscow State University, Moscow, Russia

11 ³Department of Intensive Care, Sklifosovsky Research Institute of Emergency Medicine of
12 the Moscow Healthcare Department, Moscow, Russia

13 ⁴Laboratory of Morphogenesis and Tissue Reparation, Faculty of Medicine, Lomonosov
14 Moscow State University, Moscow, Russia

15
16 ***Corresponding author: Rubina Kseniya kseniiarubina1971@gmail.com**
17

18 **Abstract**

19 COVID-19 pandemic has posed a severe healthcare challenge calling for an integrated
20 approach in determining the clues for early non-invasive diagnostics of the potentially severe cases
21 and efficient patient stratification.

22 Here we analyze the clinical, laboratory and CT scan characteristics associated with high
23 risk of COVID-19-related death outcome in the cohort of severely-ill patients in Russia. The data
24 obtained reveal that elevated dead lymphocyte counts, decreased early apoptotic lymphocytes,
25 decreased CD14+/HLA-Dr+ monocytes, increased expression of JNK in PBMCs, elevated IL-17
26 and decreased PAI-1 serum levels are associated with a high risk of COVID-19-related mortality
27 thus suggesting them to be new prognostic factors. This set of determinants could be used as early
28 predictors of potentially severe course of COVID-19 for trials of prevention or timely treatment.
29

30 **Keywords:** COVID-19, SARS-CoV-2, patient prognosis, clinical outcomes, COVID-19-
31 related death.

32 **Funding:** The reported study was funded by RFBR according to the research project №
33 20-24-60029.
34

35 The ongoing wave of COVID-19 infections resulting from an outbreak, which initially
36 started in Wuhan in China, has reached alarming proportions across the globe, as reported by the
37 World Health Organization (WHO) ¹. The unprecedented challenge with SARS-CoV-2 infection
38 calls for an integrated approach, encompassing the development of effective vaccines to prevent
39 the spread of the disease, search for new drugs aimed at lowering the viral load and preventing the
40 complications, and quest for the clues to early diagnostics of a severe course of the disease.

41 The clinical spectrum of COVID-19 manifestations appears to be remarkably wide, ranging
42 from asymptomatic infection, mild upper respiratory tract illness to severe viral pneumonia with
43 respiratory failure, systemic inflammation, disseminated intravascular coagulation, multiorgan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 failure and even death ²⁻⁴. Older age, diabetes and cardiovascular comorbidities are among the
45 highest risk factors influencing the disease severity and the clinical outcome of SARS-CoV-2
46 infection ^{4,5}. However, severe COVID-19 has been registered not only in elderly patients or
47 patients suffering from comorbidities, but also in apparently healthy young people ^{6,7}. The
48 development of new prognostic algorithms for differential diagnostics to predict and reduce the
49 severity and complications of COVID-19 remains essential.

50 The data obtained in the present study reveal novel prognostic factors associated with high
51 risk of COVID-19-related death overtime in patients with severe COVID-19. These include: the
52 elevated dead lymphocyte counts, decreased early apoptosis of lymphocytes, decreased CD14+,
53 HLA-Dr+ (human leukocyte antigen D related) monocytes, increased JNK (c-Jun N-terminal
54 kinase) expression in PBMCs (peripheral blood mononuclear cell), increased IL-17 and decreased
55 PAI-1 (plasminogen activator inhibitor-1) serum level. The prognostic value of each determinant
56 can potentially impact decision-making on the level of healthcare and require more extensive
57 follow-up strategies.

58 To the best our knowledge this is the first integrated study based on the Russian population
59 aimed to reveal the original prognostic COVID-19-related death factors.

60 **Material and methods**

61 *Study design and clinical workflow*

62 The present study was a single-center retrospective study carried out on a cohort of 52
63 symptomatic adult patients with the confirmed SARS-CoV-2 infection, admitted to intensive care
64 unit (ICU) of N.V. Sklifosovsky Research Institute for Emergency Medicine, Moscow from April
65 to July 2020. Demographic, clinical, and laboratory data were recorded at admission. The study
66 was approved by the ethics committee of Sklifosovsky Research Institute of Emergency Medicine
67 of the Moscow Healthcare Department (protocol #5-120, issued on 01.04.2020). The need for
68 written patient consent was waived by the ethics committee of the hospital because laboratory
69 investigations were conducted according to the local standard. The local ethical committee
70 approved the retrospective study.

71 Nasopharyngeal swabs were collected from all patients, followed by RT-PCR assay to
72 confirm the SARS-CoV-2 infection. Philips Ingenuity Core 128 CT Scanner (Netherlands) was
73 used for all examinations. In all cases, semi-quantitative CT scoring (severity ranging from 0 to 4)
74 was evaluated according to the protocol recommended by Moscow Healthcare Department
75 adapted from the International Protocols and enriched with local experience ⁸.

76 Routine blood tests were carried out for all patients and the following parameters were
77 evaluated: white blood cells (WBC), lymphocytes, monocytes, neutrophil, red blood cell (RBC),
78 platelet counts, levels of hemoglobin, serum total protein, albumins, globulins, bilirubin, urea,
79 creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate
80 dehydrogenase (LDH), creatine kinase (CK), prothrombin, fibrinogen, D-dimer levels, activated
81 partial thromboplastin time (APTT) and the international normalized ratio (INR).

82 *Biochemical parameters analysis in blood serum and PBMCs*

83 In addition to blood tests routinely and periodically performed in hospital, we assessed the
84 levels of plasminogen (PLG), plasminogen activator inhibitor 1 (PAI-1), IL-1 α , IL-17,
85 transforming growth factor beta (TGF β), tumor necrosis factor alpha (TNF α), and adiponectin
86 (ADP) in blood serum. Blood serum was collected and immediately frozen. Commercially
87 available ELISA kits (SEA605Hu for ADP, SEA071Hu for IL-1 α , SEA063Hu for IL-17,
88 SEA532Hu for PAI-1, SEB236Hu for PLG, SEA124Hu for TGF β , and SEA133Hu for TNF α
89 (Cloud-Clone Corp., Wuhan, Hubei) were used to evaluate the corresponding analytes according

90 to the manufacturers' protocols. The 3,3', 5,5'-tetramethylbenzidine (TMB) was used as a
 91 chromogen and the maximum absorption wavelength of 450 nm was detected using a microplate
 92 reader Multiscan Ascent (Thermo Fisher). The experiments were performed in duplicate.

93 Whole blood specimens were collected into EDTA-containing tubes either directly labelled
 94 with antibodies or subjected to PBMC purification using Lympholyte-H (Cedarlane) density
 95 gradient centrifugation. Antibodies against the following surface markers were applied for whole
 96 blood sample labelling: CD95 (mouse monoclonal anti-hu CD95-FITC 1F-362-T100, EXBIO),
 97 CD14 (mouse monoclonal anti-hu CD14-PE Conjugated Antibody A07764, Beckman Coulter)
 98 and HLA-Dr (HLA-Dr-FITC Conjugated Antibody, IM1638U, Beckman Coulter). Isotypic non-
 99 immune IgG (IgG1 Mouse-FITC Isotype Control, A07795, Beckman Coulter) was used as a
 100 control. For lymphocyte death analysis, PBMCs were stained with anti-CD45, Annexin V, 7AAD
 101 (mouse monoclonal anti-hu CD45-FITC Conjugated Antibody A07782 Beckman Coulter;
 102 Annexin V-FITC Kit-AAD Kit, IM3614, Beckman Coulter; 7-AAD Viability Dye A07704,
 103 Beckman Coulter). Labelled cells were analysed by flow cytometry with CYTOMICS FC500 flow
 104 cytometer (Beckman Coulter) and CXP software. Lymphocyte and monocyte populations were
 105 gated on FSC vs. SSC plot. The following parameters were assessed: the absolute number per 1 μ l
 106 and the percentage of dead lymphocytes (CD45+/7AAD+), the percentage of early (Annexin
 107 V+/7AAD) and late apoptotic (Annexin V+/7AAD+) lymphocytes as well as the percentage of
 108 CD95+ lymphocytes and HLA-Dr+ monocytes (CD14+/HLA-Dr+). The gating strategy is shown
 109 in **Supplementary figure 1**.

110 PBMC lysates were prepared using protease inhibitor Gordox®, and the apoptotic marker
 111 expression, such as Akt, Bad, Bcl-2, Caspase-8, Caspase-9, JNK and p53 was evaluated using
 112 Milliplex®MAP (Early Apoptosis 7-plex Magnetic Bead Kit, cat#48-660MAG) assay and
 113 Luminex® (USA). The values for each parameter are presented as Median Fluorescence Intensity
 114 (MFI). The experiments were performed in duplicate.

115 ***Outcome and exposures***

116 The outcome used in the survival analysis in the current study was COVID-19-related death,
 117 defined on the basis of International Classification of Diseases 10 code U07.1 (COVID-19, virus
 118 identified), recorded as either a primary underlying or secondary cause of death.

119 With respect to potential risk factors assessed as exposures, we obtained data for sex, age,
 120 body mass index (BMI), tobacco smoking status, chest CT severity score (the worst CT imaging
 121 data per patient presented in Table 1). Patients were grouped by age as: younger than 40 years, 40-
 122 49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years or older. BMI was grouped as: less
 123 than 30 (no evidence of obesity), 30-34.9 (obese class I), 35-39.9 (obese class II), and 40 kg·m⁻²
 124 or higher (obese class III). Tobacco smoking status was identified as smoker, non-smoker (not a
 125 current smoker), or missing data. Chest CT score was grouped as 1-2 or 3-4.

126 **Table 1. Cohort description with COVID-19 deaths by patient characteristics.** Data are
 127 presented as n (%). BMI = body mass index.

	All patients (n = 52)	Deaths (n = 11)
Sex		
Male	28 (54%)	5 (45%)
Female	24 (46%)	6 (55%)
Age, years		
18-39	3 (6%)	0 (0%)
40-49	8 (15%)	1 (9%)

50-59	12 (23%)	1 (9%)
60-69	11 (21%)	3 (27%)
70-79	7 (13%)	1 (9%)
80+	11 (21%)	5 (45%)
BMI, kg·m⁻²		
<30	31 (60%)	7 (64%)
30-34.9	16 (31%)	4 (36%)
35-39.9	2 (4%)	0 (0%)
40+	3 (6%)	0 (0%)
Tobacco smoking status		
Non-smoker	41 (79%)	6 (55%)
Smoker	2 (4%)	0 (0%)
Missing data	9 (17%)	5 (45%)
Chest CT severity score (the worst CT imaging data per patient)		
0-2	32 (62%)	2 (18%)
3-4	20 (38%)	9 (82%)

128 Routine blood test parameters were organized into three groups relying on the reference
 129 range: lower, within, or higher the reference range. The accepted reference values of the blood
 130 tests parameters are presented in Supplementary **Table 1**. In case the data of several measurements
 131 were available, the mean of all measurements was calculated and used for subsequent analysis.
 132 Biochemical serum and leukocyte parameters categorization are presented in **Supplementary**
 133 **table 2**.


134 *Statistical analysis*

135 Categorical variables are described as numbers and percentages. Continuous variables are
 136 reported as the median (interquartile range). To identify risk factors associated with COVID-19-
 137 related death, a survival analysis of the outcome was performed: time was defined as the time from
 138 hospital admission to the end of a follow-up (hospital discharge or death) and the event defined as
 139 death or hospital discharge after recovery. The Kaplan-Meier method was used to analyze
 140 cumulative survival curves and their difference between the groups categorized by type of
 141 exposure compared by log-rank tests. Exposures with difference between the groups $P < 0.05$ by
 142 log-rank tests were considered significant. We created univariable Cox proportional hazards
 143 survival analysis models for the evaluated parameters of each patient to test for their association
 144 with survival. We also created multivariable Cox proportional hazards survival analysis models to
 145 identify independent risk factors. Complete cases were considered. The variables included in the
 146 final models were based on clinical and scientific knowledge and the results of univariable
 147 analyses. Considering the small size of the cohort and to avoid overfitting in the model, we created
 148 three separate final multivariable Cox models, with variables grouped as clinical characteristics
 149 and hematological results; clinical biochemical routine blood test results; laboratory blood
 150 findings. The data were analyzed in R studio v.1.2.5042 with the survival and survminer packages.
 151

152 **Results**


153 A total of 52 patients, aged 26-88, with confirmed SARS-CoV-2 infection were included in
 154 the study cohort (**Table 1**). The median age was 64 (54-76) years; the median BMI was 28.7 (25.8-
 155 31.1) kg·m⁻²; 28 patients (54%) were men. 1 patient was admitted to ICU with CT score 0; 13
 156 patients with CT score 1; 18 patients with CT score 2; 13 patients with CT score 3, and 4 patients
 157 with CT score 4. Overall, 11 (21%) patients died.

158 The survival analysis was performed with time defined as a period from hospital admission
159 to the end of the follow-up (hospital discharge or death) and event defined as death or hospital
160 discharge after recovery (**Figure 1**). The Kaplan-Meier survival function analysis revealed that
161 20-day survival probability was 91.0% (95% CI 82.9-99.9%), 40-day survival probability was
162 64.3% (95% CI 46.1-89.5), 60-day survival probability was 48.2% (95% CI 28.7-81.0%).



163 **Figure 1. Kaplan-Meier survival curve with associated 95% confidence intervals**
164 **(shaded area) for patients admitted with COVID-19 infection to ICU of N.V. Sklifosovsky**
165 **Research Institute for Emergency Medicine, Moscow from April to July 2020.** The fraction
166 of survival is expressed on the y-axis, while time (days) of the observation period is expressed on
167 the x-axis. Vertical traits indicate censored data (hospital discharge).
168


169
170 We performed the Kaplan-Meier analysis to compare the survival over time between
171 different groups of patients for each variable. The Kaplan-Meier survival plots for the clinical and
172 routine blood test factors with statistically significant results are presented in **Figure 2**. We found,
173 that the risk of COVID-19-related death over time was significantly increased in patients with CT
174 score 3-4 at admission ($P = 0.042$), patients on pulmonary ventilation ($P = 0.00047$), patients with
175 WBC count more than $11.8 \cdot 10^3/\mu\text{l}$ ($P = 0.001$), neutrophil count more than $8.2 \cdot 10^3/\mu\text{l}$ ($P =$
176 0.00027), lymphocyte count less than $1.1 \cdot 10^3/\mu\text{l}$ ($P = 0.018$), increased serum levels of globulins
177 more than 30 g/l ($P = 0.046$), urea more than 7.2 mM ($P = 0.01$), CK more than 200 U/l ($P =$
178 0.023), prothrombin less than 78% ($P = 0.023$), INR more than 1.17 ($P = 0.02$) and D-dimer more
179 than 2 mg/l ($P = 0.0078$). Gender, age, BMI, tobacco smoking status and other parameters of
180 routine blood tests were not associated with statistically significant differences as revealed by
181 Kaplan-Meier analysis (**Supplementary figure 2**).



182
183
184
185
186
187
188

Figure 2. Kaplan-Meier survival curves for patients grouped by clinical and routine blood test parameters. The fraction of survival is expressed on the y-axis, while time (days) of the observation period is expressed on the x-axis. Vertical traits indicate censored data (hospital discharge). *P* values of log-rank tests are indicated for each graph. Reference group is shown in red.

189 The Kaplan-Meier survival plots for the biochemical test factors being statistically
190 significant are presented in **Figure 3**. We found, that the risk of COVID-19-related death over
191 time was significantly increased in patients with more than 100 dead lymphocytes in 1 μ l ($P =$
192 0.0026), less than 5% of early apoptotic lymphocytes ($P = 0.0081$), less than 85% of CD14+/HLA-
193 Dr+ monocytes ($P = 0.029$), increased expression of JNK in PBMCs (>200 MFI, $P = 0.034$),
194 increased serum levels of IL-17 (>7 pg/ml, $P = 0.037$) and decreased PAI-1 serum levels (< 40
195 pg/ml, $P = 0.00073$). Percentage of dead and late apoptotic lymphocytes, percentage of CD95+
196 lymphocytes, expression of Akt, Bad, Bcl-2, Caspase-8, Caspase-9, p53 and serum levels of PLG,
197 IL-1 α , TGF β , TNF α , adiponectin were not associated with statistically significant differences in
198 survival as revealed by Kaplan-Meier analysis (**Supplementary figure 3**).
199



200
201 **Figure 3. Kaplan-Meier survival curves for patients grouped by biochemical test**
202 **parameters.** The fraction of survival is expressed on the y-axis, while time (days) of the
203 observation period is expressed on the x-axis. Vertical traits indicate censored data (hospital
204 discharge). P values of log-rank tests are indicated for each graph. Reference group is shown in
205 red.
206

207 To identify the independent risk factors, we created multivariate Cox proportional hazards
208 survival analysis models separately for clinical characteristics and hematology results; for clinical
209 biochemical routine blood test results and for laboratory blood findings (**Table 2**). On multivariate
210 Cox proportional hazards survival analysis of clinical and routine hematological test parameters,
211 ventilation (HR 55.66 (2.2-1388.4), $P = 0.014$) and platelet count (HR 1.01 (1.002-1.027), $P =$
212 0.017) were found to be the independent prognostic factor for COVID-19 related death. On
213 multivariate analysis of clinical biochemical routine blood test results, the serum levels of
214 globulins (HR 1.32 (1.03-1.70), $P = 0.026$), CK (HR 1.02 (1.005-1.04), $P = 0.013$) and D-dimer
215 (3.41 (1.11-10.50), $P = 0.033$) were found to be the independent prognostic factor for COVID-19
216 related death. On multivariate analysis of laboratory blood findings, the serum level of IL-17 (HR
217 1.07 (1.001-1.14), $P = 0.046$) and PAI-1 (HR 0.82 (0.69-0.98), $P = 0.026$) were found to be the
218 independent prognostic factor for COVID-19 related death. The results of univariable Cox

219 proportional hazards survival analysis for each parameter are presented in **Supplementary table**
 220 **3**.
 221

222 **Table 2. Multivariable Cox proportional hazards survival analysis models for 3 groups**
 223 **of prognostic factors.** HR – hazard ratio, CI – confidence interval, Inf – infinite. * – $P < 0.05$.

Parameter	HR (95% CI)	P value
Clinical characteristics and hematology results		
CT	0-2: reference 3-4: 0.52 (0.03-7.85)	0.634
Ventilation	No: reference Yes: 55.66 (2.23-1388.40)	0.014 *
WBC, $10^3/\mu\text{l}$	0.58 (0.11-2.96)	0.509
Neutrophil count, $10^3/\mu\text{l}$	2.68 (0.57-12.48)	0.210
Lymphocyte count, $10^3/\mu\text{l}$	0.29 (0.01-6.93)	0.447
Monocyte count, $10^3/\mu\text{l}$	0.15 (0.00-1564.4)	0.692
Platelet count, $10^3/\mu\text{l}$	1.01 (1.002-1.027)	0.017 *
Clinical biochemical routine blood test results		
Globulins, g/l	1.32 (1.03-1.70)	0.026 *
Urea, mM	0.88 (0.62-1.20)	0.467
Creatinine, μM	1.02 (0.99-1.10)	0.244
ALT, U/l	0.99 (0.93-1.00)	0.638
AST, U/l	1.01 (0.98-1.00)	0.572
LDH, U/l	0.99 (0.985-1.00)	0.705
CK, U/l	1.02 (1.005-1.04)	0.013 *
D-dimer, mg/l	3.41 (1.11-10.50)	0.033 *
Laboratory blood findings		
Dead lymphocyte count	1.02 (1.00-1.04)	0.054
Early lymphocyte apoptosis	1.09 (0.77-1.55)	0.624
CD14+, HLA-Dr+ monocytes, %	0.96 (0.91-1.01)	0.108
IL-17, pg/ml	1.07 (1.001-1.14)	0.046 *
IL-1 α , pg/ml	1.09 (0.90-1.31)	0.385
PLG, $\mu\text{g/ml}$	0.66 (0.32-1.32)	0.238
PAI-1, pg/ml	0.82 (0.69-0.98)	0.026 *
TNF α , pg/ml	0.90 (0.68-1.19)	0.464
TGF β , pg/ml	1.00 (1.00-2.02)	0.069
ADP, $\mu\text{g/ml}$	0.56 (0.30-1.08)	0.083

224
 225
 226

Discussion

227 With the rapid spread of COVID-19 around the world since its outbreak in early 2020, it has
 228 stirred up an international concern and still remains so. Chest CT imaging has been recognized to
 229 play a pivotal role in monitoring COVID-19 disease progression and predicting adverse prognosis.
 230 We found that CT score 3-4 at admission and pulmonary ventilation significantly increase the risk
 231 of COVID-19-related death over time (**Figure 2**) that is in accordance with the previously
 232 published data^{2,9-14}.

233 A compelling body of evidence indicate that clinical and routine blood test factors such as
 234 an increased WBC count^{2,15-22}, elevated neutrophil count^{2,16-23}, low lymphocyte count^{2,4,9,17,18,20-}
 235 ²², elevated urea^{2,15,19,21-24}, upregulated CK^{2,4,9,18,22} and increased level of serum globulins²³ or

236 immunoglobulins²⁵ are statistically significant and strongly correlate with the adverse outcome in
237 COVID-19 patients. Our data also confirm the recent papers (**Figure 2**). Previously, neutrophil-
238 lymphocyte ratio (NLR) was shown to be a prognostic marker of systemic inflammation in various
239 pathological conditions^{26,27}. Moreover, NLR was found to have a high prognostic value in
240 COVID-19 patients with the increase in neutrophils and the decrease in the total number of
241 lymphocytes in the peripheral blood. Generally, the COVID-19 patients with increased NLR have
242 a poor prognosis and a high risk of death²⁸. Earlier, it has been demonstrated that COVID-19
243 patients with severe respiratory failure exhibit low HLA-Dr expression on CD14+ monocytes
244 relative to that of mild COVID-19 patients or healthy volunteers^{29,30}. Xu and co-authors
245 hypothesized that monocytes in severe COVID-19 displayed a phenotype similar to
246 immunosuppressive monocytic myeloid-derived suppressor cells (CD14+/HLA-DR-/lo)³⁰.
247 Interestingly, the expression of HLA-Dr on monocytes from healthy donors decreased following
248 the cultivation in media with plasma from patients with COVID-19 who have immune
249 dysregulation³¹. Our results also indicate that the risk of COVID-19-related death over time is
250 significantly increased in patients with elevated neutrophil and decreased lymphocyte counts.
251 Moreover, we have defined that the decrease in CD14+/HLA-Dr+ monocyte fraction are
252 significant predictors of disease severity in COVID-19 patients (**Figure 3**).

253 The biological role of lymphocyte apoptosis in infectious disease is ambiguous; whether it
254 operates as an intrinsic protective mechanism or mediates a severe course of the disease still
255 remains unclear. Lymphocytes can undergo extensive and ostensibly out-of-control apoptosis
256 during severe infections, potentially contributing to immunosuppression³². In the majority of viral
257 infections, lymphocytes are subjected to apoptosis, which is considered to be a defense mechanism
258 preventing the spread of infection without a local inflammatory reaction³³. Although lymphocyte
259 count can be initially augmented at the onset of COVID-19, its subsequent decline in the course
260 of infection may result in lymphocytopenia and immunodeficiency associated with an increased
261 COVID-19 severity³⁴. The frequency of peripheral blood lymphocyte subpopulations, including
262 T-CD4+, T-CD8+, NK, B cells, and monocytes, and their apoptosis pattern was assessed in Iranian
263 COVID-19 patients. The authors reported a marked increase in apoptosis of mononuclear cells
264 from COVID-19 patients as compared to control, however no association with mortality has been
265 addressed in this study³⁵. Our data indicate that elevated dead lymphocyte counts are associated
266 with COVID-19 mortality (**Figure 3**), however, early lymphocyte apoptosis is rather a protective
267 mechanism reflecting the intensity of the adaptive cell immune response to an infectious agent,
268 whereas a decrease in the early apoptosis of lymphocytes is an important predictor of COVID-19-
269 related mortality (**Figure 3**).

270 Elevated plasma D-dimer is a well-established prognostic factor for adverse outcome in
271 respiratory diseases and COVID-19^{28,36,37}. Our results go along with these previously published
272 data and ascertain that the COVID-19-related death over time is significantly increased in patients
273 with augmented D-dimer (**Figure 2**).

274 A potentially practical opportunity was proposed by the sustained elevated production of IL-
275 6^{2,4,9,15,16,18,19,21-23,38}, IL-1, IL-2R, IL-8, IL-10^{2,9} and some other blood circulating factors, whose
276 early evaluation anticipated disease progression and duration of hospital stay of COVID-19
277 patients³⁹. Such interleukins as IL-1 β , IL-6, IL-17A, TNF- α , and monocyte chemoattractant
278 peptide (MCP)-1 were identified in patients with severe COVID-19⁴⁰. Huang et al.⁴¹
279 demonstrated the upregulated levels of IL-1 β , IL-6, IL-8, IL-17, interferon γ (IFN- γ), TNF- α in
280 patients with COVID-19 as compared to healthy donors. The same study revealed increased
281 plasma concentrations of MCP-1 and TNF- α in patients with COVID-19 admitted to the ICU.
282 Similarly, Chen and co-authors⁶ reported the correlation between high concentrations of plasma
283 IL-6 and TNF- α and the severe course of COVID-19. In contrast, in the study by Kang and co-
284 authors these cytokines, including IL-1 β , IL-12p40, and IL-17 were undetectable in patients with
285 severe COVID-19⁴². Several clinical trials investigating interleukin inhibitors (IL-1 inhibitor
286 anakinra, and IL-6 inhibitors tocilizumab or sarilumab) revealed that IL-1 inhibition, but not IL-6

287 inhibition, was associated with a significant reduction of mortality in patients admitted to hospital
288 with COVID-19, ARDS (acute respiratory distress syndrome), and hyperinflammation⁴³.

289 IL-17 is a promising target in COVID-19, since it operates upstream of both, IL-1 and IL-6
290⁴⁴. Although the pathogenic role of IL-17 has been suggested previously, this cytokine was not
291 detected as a mortality risk factor in COVID-19 patients^{40,44}. MERS-CoV infection was reported
292 to be associated with an increased serum level of IL-17, although its correlation with mortality
293 was not demonstrated⁴⁵. IL-17 polymorphisms are associated with susceptibility and poor
294 prognosis in acute respiratory distress syndrome⁴⁶. Meanwhile, in obese patients with confirmed
295 COVID-19, IL-17 boosts neutrophil recruitment via induction of inflammatory cytokine
296 production by respiratory epithelium, smooth muscle cells and fibroblasts resulting in respiratory
297 dysfunction⁴⁰.

298 In the present study IL-1 α , TNF- α and TGF- β were not associated with the statistically
299 significant difference in patient survival (**Supplementary figure 3**); however, IL-17 and PAI-1
300 were determined as independent prognostic factors for COVID-19 related death (**Figure 3**),
301 underlying their potential significance as predictors of mortality for patients with COVID-19.

302 PAI-1 is a well-known inhibitor of the plasminogen activators (tissue plasminogen activator
303 – tPA, and urokinase – uPA) and hence the overall fibrinolysis⁴⁷. Of note, PAI-1 levels are
304 increased in hypertension, obesity, diabetes, cardiovascular diseases, and old age, which is
305 consistent with the scenario of COVID-19 disease^{48,49}. Plasmin, and other proteases, may cleave
306 the furin site in the S protein of SARS-CoV-2, thus increasing the virus virulence. Moreover, the
307 dysregulation in fibrinolytic homeostasis in COVID-19 patients with excessive fibrin degradation
308 may result in an unbalanced fibrinolysis inducing multiple organ hemorrhage^{50,51}.
309 Hyperfibrinolysis resulting from excessive plasmin activity is also associated with elevated D-
310 dimer in severely-ill COVID-19 patients.

311 While Umemura et al. reported an unchanged PAI-1 level in COVID-19 patients⁵², several
312 other groups detected the increased levels of PAI-1, tPA and uPA in COVID-19 patients as
313 compared to healthy controls^{53,54}. Zou and co-authors demonstrated that high levels of tPA and
314 PAI-1 were associated with worse respiratory status in patients hospitalized with COVID-19⁴⁸. It
315 has been found that overproduced PAI-1 binds to specific receptors on macrophages and
316 upregulates the production of proinflammatory cytokines and chemokines, which further activate
317 the innate immune cells within the infected lungs resulting in lung damage. In turn, high hypoxic
318 environment additionally stimulates PAI-1 production creating a vicious cycle of cytokine storm
319 generated during SARS virus pathogenesis⁵¹. In contrast, our data indicate that COVID-19-related
320 mortality is associated with decreased PAI-1, establishing that PAI-1 being the constituent
321 component of the fibrinolytic system plays an important role in COVID-19 pathogenesis. The
322 explanation for the reduced PAI-1 content in the critically-ill patients may reside in compensation
323 for the hyperactivation of plasminogen activator system, reflecting the exhaustion of plasmin
324 inhibitors (**Figure 3**).

325 The C-Jun NH2-terminal kinase (JNK1/JNK2) pathway activation ultimately leads to
326 various cellular effects such as inflammatory response, cell proliferation, survival or even
327 apoptosis. JNK signaling pathway was suggested to play a prominent role in immune response to
328 viral infection due to activation of several interleukins (IL-2, IL-4) and IFN- γ ⁵⁵. To uncover the
329 mechanisms of JNK-mediated inflammation in COVID-19, Shirato and Kizaki carried out an *in*
330 *vitro* study and analyzed the effects of SARS-CoV-2 spike protein S1 subunit on murine and
331 human macrophages. Exposure to S1 subunit activated pro-inflammatory mediators (nuclear
332 factor- κ B (NF- κ B) and JNK) signaling pathways via the activation of a toll-like receptor 4 (TLR4)
333 on macrophage surface. Pro-inflammatory cytokine (TNF- α , IL-6, IL-1 β , and nitric oxide)
334 production induced by S1 was abrogated by specific inhibitors of NF- κ B and JNK pathways⁵⁶.

335 In line with the suggested strategy for inhibition of JNK pathway in COVID-19 critically-ill
336 patients as a promising therapeutic approach⁵⁷, here we present the first clinical study revealing
337 the increased JNK expression in PBMCs to be a significant prognostic marker of COVID-19-
338 related mortality (**Figure 3**). It is tempting to speculate that the elevated JNK, which has been

339 demonstrated to induce TLR4-mediated apoptosis in various types of cells^{56,58}, and the decreased
340 level of lymphocyte early apoptosis in severe COVID-19 patients revealed in the present study are
341 intertwined. However, this assumption needs further investigation.

342 In conclusion, this study unveiled an integrated set of immunological features and new
343 prognostic markers of patients with severe COVID-19 that are significant predictors of the related
344 mortality. The obtained results suggest a high risk of COVID-19-related death overtime in patients
345 with elevated dead lymphocyte counts, decreased early apoptosis of lymphocytes, reduced fraction
346 of CD14+/HLA-Dr+ monocytes, increased JNK expression in PBMCs, elevated IL-17 and
347 decreased PAI-1 serum levels. Gender, age, BMI, tobacco smoking status and several parameters
348 of routine blood tests (**Supplementary figure 2**) were not statistically significant.

349 Our analysis revealed novel determinants of a high COVID-19-related death risk overtime
350 that can provide for patient stratification at admission to ICU or point to the potential requirement
351 of a more extensive follow up treatment strategies.

352
353
354

Limitations

355 Our study has some limitations. First, the cohort might not be fully representative as the
356 study was a single center one and only the patients admitted to ICU were included. Therefore, a
357 relatively high mortality rate was detected, which cannot reflect the actual COVID-19 mortality
358 in a population. Second, our results might be limited by the sample size. Third, the outcomes were
359 evaluated at the end of the follow-up period instead of a fixed time period during the course of the
360 disease. Fourth, not all laboratory tests were done in all patients, however, the data were missing
361 completely at random. Hence, the interpretation of our results might be limited.

362 However, we believe that our study uncovers some important tendencies that should be
363 further considered with the relation to COVID-19 mortality. As far as we are aware, this is the first
364 retrospective cohort study among patients with COVID-19 in Russia that evaluated the
365 biochemical parameters in blood serum different from those that are routinely used in healthcare
366 practice. The obtained results may provide a rationale for testing these new parameters as novel
367 markers of COVID-19 severity and point to potential targets for therapeutical intervention in quest
368 to improve the outcomes.

Contribution

369 Rubina K. and Semina E. conceived and designed the study. Petrikov S. managed intensive care
370 unit facility, resources and patients' admission. Shabanov A., Andreev Yu., Borovkova N.,
371 Kulabukhov V. collected and managed the patient's data and performed the biochemical tests.
372 Shmakova A. performed the statistical analysis and described the results. Rubina K. and Semina
373 E. contributed to the writing, review and editing of the manuscript. Evseev A., Popugaev K.,
374 Petrikov S. made a substantial contribution to the design of the study.

Supplementary tables and figures

376 **Supplementary table 1. The accepted reference values of the routine blood tests**
377 **parameters.**
378

Parameter	Reference values	Units
RBC count	3.7-5.4	10 ¹² /l
Hemoglobin	120-140	g/l
WBC count	3.8-11.8	10 ³ /μl
Neutrophil count	1.9-8.2	10 ³ /μl

Neutrophils %	42.7-76.8	%
Lymphocyte count	1.1-3.8	10 ³ /μl
Lymphocytes %	16-45.9	%
Monocyte count	0.2-0.9	10 ³ /μl
Monocytes %	4.3-11.0	%
Platelet count	179-408	10 ³ /μl
Total protein	66-83	g/l
Albumins	35-52	g/l
Globulins	20-30	g/l
Total bilirubin	<19	μM
Urea	<7.2	mM
Creatinine	<96	μM
ALT	<34	U/l
AST	<31	U/l
LDH	<247	U/l
CK	<200	U/l
APTT	25.1-36.5	S
Prothrombin	78-142	%
INR	0.64-1.17	-
Fibrinogen	2.2-4.98	g/l
D-dimer	<0.5	mg/l

379 **Supplementary table 2. Categorization of biochemical parameters.** Reference group is
380 highlighted in bold. MFI – Median Fluorescence Intensity.

Parameter	Groups			Units
Dead lymphocytes count	< 100	>100		1/μl
Dead lymphocytes %	< 1.5	>1.5		%
Early apoptotic lymphocytes	<5%	5-10%	>10%	%
Late apoptotic lymphocytes	< 0.1%	>0.1%		%
CD95+ lymphocytes	<37	37-46	>46	%
CD14+, HLA-Dr+ monocytes	<85%	>85%		%
Akt	< 107	>107		MFI
Bad	< 101	>101		MFI
Bcl-2	< 20.25	>20.25		MFI
Caspase-8	< 81.25	>81.25		MFI
Caspase-9	< 200	>200		MFI
JNK	< 200	>200		MFI
p53	< 72.25	>72.25		MFI
IL-17	<7	>7		pg/ml
PLG	< 20	>20		μg/ml
IL-1α	< 0.3	>0.3		pg/ml
PAI-1	< 40	>40		pg/ml
TGFβ	< 30	>30		pg/ml
TNFα	< 11	>11		pg/ml
Adiponectin	<5	5-10	>10	μg/ml

381


382 **Supplementary table 3. Univariable Cox proportional hazards survival analysis**
 383 **models.** HR – hazard ratio, CI – confidence interval, Inf – infinite. * – $P < 0.05$, ** – $P < 0.01$.

Parameter	HR (95% CI)	P value
Demographic and clinical characteristics		
Gender	F: <i>reference</i> M: 1.13 (0.34-3.78)	0.838
Age, years	18-39: 0.00 (0.00-Inf)	0.999
	40-49: 1.18 (0.07-19.52)	0.909
	50-59: <i>reference</i>	
	60-69: 2.24 (0.23-21.81)	0.488
	70-79: 0.60 (0.03-10.57)	0.728
BMI, kg·m ⁻²	80+: 2.53 (0.28-22.59)	0.406
	<30: <i>reference</i>	
	30-34.9: 0.95 (0.28- 3.24)	0.930
	35-39.9: 0.00 (0.00-Inf)	0.999
Smoking	40+: 0.00 (0.00-Inf)	0.999
	Non-smoker: <i>reference</i> Smoker: 0.00 (0.00-Inf)	0.999
CT	0-2: <i>reference</i>	
	3-4: 4.40 (0.94-20.63)	0.06
Ventilation	No: <i>reference</i>	
	Yes: 9.86 (2.10-46.23)	0.004 **
Hematology results		
RBC count, 10 ¹² /l	0.75 (0.3-1.86)	0.534
Hemoglobin, g/l	0.99 (0.95-1.02)	0.421
WBC count, 10 ³ /μl	1.16 (1.03-1.30)	0.014 *
Neutrophil count, 10 ³ /μl	1.17 (1.03-1.33)	0.013 *
Neutrophil, %	1.11 (1.01-1.22)	0.025 *
Lymphocyte count, 10 ³ /μl	0.22 (0.04-1.12)	0.068
Lymphocyte, %	0.86 (0.75-0.99)	0.036 *
Monocyte count, 10 ³ /μl	0.37 (0.01-19.28)	0.619
Monocyte, %	0.74 (0.54-1.01)	0.056
Platelet count, 10 ³ /μl	1.003 (0.996-1.009)	0.423
Clinical biochemical routine blood test results		
Total serum protein, g/l	1.01 (0.94-1.09)	0.807
Albumins, g/l	0.91 (0.82-1.01)	0.071
Globulins, g/l	1.15 (1.02-1.30)	0.021 *
Total bilirubin	0.99 (0.96-1.02)	0.534
Urea, mM	1.09 (1.04-1.15)	0.001 **
Creatinine, μM	1.005 (1.002-1.009)	0.006 **
ALT, U/l	1.002 (1.0004-1.003)	0.013 *

AST, U/l	1.001 (1.0002-1.001)	0.010 *
LDH, U/l	1.001 (1.0002-1.001)	0.005 **
CK, U/l	1.003 (1.001-1.005)	0.002 **
APTT, s	1.01 (0.998-1.022)	0.093
Prothrombin, %	0.99 (0.96-1.01)	0.391
INR	1.17 (0.66-2.07)	0.591
Fibrinogen, g/l	1.26 (0.95-1.67)	0.105
D-dimer, mg/l	1.26 (1.02-1.55)	0.032 *
Laboratory blood findings		
Dead lymphocytes, count/ μ l	1.009 (1.003-1.013)	0.001 **
Dead lymphocytes, %	2.45 (1.21-4.96)	0.013 *
Early lymphocyte apoptosis	0.91 (0.77-1.06)	0.216
Late lymphocyte apoptosis	3.08 (0.01-882.66)	0.696
CD95+ lymphocytes, %	0.98 (0.94-1.02)	0.370
CD14+/HLA-Dr+ monocytes, %	0.97 (0.95-0.99)	0.005 **
AKT	1.00 (1.00-1.00)	0.593
BAD	1.01 (1.00-1.01)	0.063
BCL2	0.90 (0.79-1.02)	0.107
Caspase 8	1.03 (0.99-1.07)	0.128
Caspase 9	1.00 (1.00-1.01)	0.258
JNK	1.00 (1.00-1.00)	0.510
P53	0.97 (0.94-1.02)	0.230
IL-17, pg/ml	1.03 (1.01-1.05)	0.001 **
IL-1 α , pg/ml	1.07 (1.02-1.13)	0.005 **
PLG, μ g/ml	1.01 (0.87-1.17)	0.916
PAI-1, pg/ml	0.96 (0.91-1.01)	0.104
TNF α , pg/ml	1.07 (0.95-1.20)	0.263
TGF β , pg/ml	1.00 (1.00-1.00)	0.159
ADP, μ g/ml	0.88 (0.73-1.06)	0.263

384


385



386


387 **Supplementary figure 1. The flow cytometry analysis.** A – Representative flow cytometry
388 graphs showing the gating strategy used to assess lymphocyte apoptosis. Forward scatter (FSC)
389 vs. side scatter (SSC) plot applied to gate the lymphocyte cell population and remove the debris.
390 Annexin-FITC-channel vs. 7AAD-channel plot used to gate early (Annexin V+/7AAD-) and late
391 (Annexin V+/7AAD+) apoptotic cells in lymphocyte population. B – Representative flow
392 cytometry graphs showing the gating strategy used to evaluate the percentage of CD14+/HLA-
393 Dr+ cells in monocyte cell population from the whole blood. Isotypic non-immune IgG (IgG1
394 Mouse-FITC Isotype Control, A07795, Beckman Coulter) was applied as a control.

395



396
397
398
399
400
401

Supplementary figure 2. Kaplan-Meier survival curves for demographic, other clinical and routine blood test parameters. The fraction of survival is expressed on the y-axis, while time (days) of the observation period is expressed on the x-axis. Vertical traits indicate censored data (hospital discharge). *P* values of log-rank tests are indicated for each graph. Reference group is shown in red.



402
403
404
405
406
407
408

Supplementary figure 3. Kaplan-Meier survival curves for other biochemical test parameters. The fraction of survival is expressed on the y-axis, while time (days) of the observation period is expressed on the x-axis. Vertical traits indicate censored data (hospital discharge). *P* values of log-rank tests are indicated for each graph. Reference group is shown in red.

409

References

- 410 1. WHO. Coronavirus Disease (COVID-19) Situation Reports.
411 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
412 (2021).
413 2. Wang, Y. *et al.* Clinical course and outcomes of 344 intensive care patients with COVID-
414 19. *American Journal of Respiratory and Critical Care Medicine* vol. 201 1430–1434
415 (2020).
416 3. Coleman, J. J., Manavi, K., Marson, E. J., Botkai, A. H. & Sapey, E. COVID-19: to be or
417 not to be; that is the diagnostic question. *Postgraduate medical journal* vol. 96 392–398
418 (2020).
419 4. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with

- 420 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054–1062
421 (2020).
- 422 5. Williamson, E. J. *et al.* Factors associated with COVID-19-related death using
423 OpenSAFELY. *Nature* **584**, 430–436 (2020).
- 424 6. Chen, G. *et al.* Clinical and immunological features of severe and moderate coronavirus
425 disease 2019. *J. Clin. Invest.* **130**, 2620–2629 (2020).
- 426 7. Zhang, S. Y. *et al.* Severe COVID-19 in the young and healthy: monogenic inborn errors
427 of immunity? *Nature Reviews Immunology* vol. 20 455–456 (2020).
- 428 8. Морозов, С. П. *et al.* Лучевая диагностика коронавирусной болезни (Covid-19):
429 организация, методология, интерпретация результатов. Версия 2 (17.04.2020). vol.
430 № ЦДТ – 2020 – II (Государственное бюджетное учреждение здравоохранения
431 города Москвы «Научно-практический клинический центр диагностики и
432 телемедицинских технологий Департамента здравоохранения города Москвы»,
433 2020).
- 434 9. Zhang, X.-B. *et al.* Risk factors for mortality of coronavirus disease-2019 (COVID-19)
435 patients in two centers of Hubei province, China: A retrospective analysis. *PLoS One* **16**,
436 e0246030 (2021).
- 437 10. Hu, Y., Zhan, C., Chen, C., Ai, T. & Xia, L. Chest CT findings related to mortality of
438 patients with COVID-19: A retrospective case-series study. *PLoS One* **15**, (2020).
- 439 11. Tabatabaei, S. M. H., Rahimi, H., Moghaddas, F. & Rajebi, H. Predictive value of CT in
440 the short-term mortality of Coronavirus Disease 2019 (COVID-19) pneumonia in
441 nonelderly patients: A case-control study. *Eur. J. Radiol.* **132**, 109298 (2020).
- 442 12. Lei, Q. *et al.* Correlation between CT findings and outcomes in 46 patients with
443 coronavirus disease 2019. *Sci. Rep.* **11**, 1103 (2021).
- 444 13. Li, K. *et al.* Radiographic findings and other predictors in adults with Covid-19. *medRxiv*
445 2020.03.23.20041673 (2020) doi:10.1101/2020.03.23.20041673.
- 446 14. Patel, U. *et al.* Age-Adjusted Risk Factors Associated with Mortality and Mechanical
447 Ventilation Utilization Amongst COVID-19 Hospitalizations—a Systematic Review and
448 Meta-Analysis. *SN Compr. Clin. Med.* **2**, 1740–1749 (2020).
- 449 15. Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to
450 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive*
451 *Care Medicine* vol. 46 846–848 (2020).
- 452 16. Li, M. *et al.* Analysis of the Risk Factors for Mortality in Adult COVID-19 Patients in
453 Wuhan: A Multicenter Study. *Front. Med.* **7**, 545 (2020).
- 454 17. Izcovich, A. *et al.* Prognostic factors for severity and mortality in patients infected with
455 COVID-19: A systematic review. *PLoS One* **15**, e0241955 (2020).
- 456 18. Huang, Y. *et al.* A cohort study of 676 patients indicates D-dimer is a critical risk factor
457 for the mortality of COVID-19. *PLoS One* **15**, e0242045 (2020).
- 458 19. Martins-Filho, P. R., Tavares, C. S. S. & Santos, V. S. Factors associated with mortality in
459 patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory
460 data. *European Journal of Internal Medicine* vol. 76 97–99 (2020).
- 461 20. Ioannou, G. N. *et al.* Risk Factors for Hospitalization, Mechanical Ventilation, or Death
462 Among 10 131 US Veterans With SARS-CoV-2 Infection. *JAMA Netw. open* **3**, e2022310
463 (2020).
- 464 21. Mesas, A. E. *et al.* Predictors of in-hospital COVID-19 mortality: A comprehensive
465 systematic review and meta-analysis exploring differences by age, sex and health
466 conditions. *PLoS One* **15**, e0241742 (2020).
- 467 22. Wang, L. *et al.* Coronavirus disease 2019 in elderly patients: Characteristics and
468 prognostic factors based on 4-week follow-up. *J. Infect.* **80**, 639–645 (2020).
- 469 23. Wu, C. *et al.* Risk Factors Associated with Acute Respiratory Distress Syndrome and
470 Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA*
471 *Intern. Med.* **180**, 934–943 (2020).

- 472 24. Cheng, A. *et al.* Diagnostic performance of initial blood urea nitrogen combined with D-
473 dimer levels for predicting in-hospital mortality in COVID-19 patients. *Int. J. Antimicrob.*
474 *Agents* **56**, 106110 (2020).
- 475 25. Zhao, Y. *et al.* Abnormal immunity of non-survivors with COVID-19: Predictors for
476 mortality. *Infect. Dis. Poverty* **9**, 108 (2020).
- 477 26. Huang, H. *et al.* Preoperative neutrophil–lymphocyte and platelet–lymphocyte ratios as
478 independent predictors of T stages in hilar cholangiocarcinoma. *Cancer Manag. Res.*
479 **Volume 11**, 5157–5162 (2019).
- 480 27. Celikbilek, M. *et al.* Neutrophil-Lymphocyte Ratio as a Predictor of Disease Severity in
481 Ulcerative Colitis. *J. Clin. Lab. Anal.* **27**, 72–76 (2013).
- 482 28. Ye, W. *et al.* Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as
483 prognostic biomarkers in COVID-19. *Respir. Res.* **21**, 169 (2020).
- 484 29. Giamarellos-Bourboulis, E. J. *et al.* Complex Immune Dysregulation in COVID-19
485 Patients with Severe Respiratory Failure. *Cell Host Microbe* **27**, 992-1000.e3 (2020).
- 486 30. Xu, G. *et al.* The differential immune responses to COVID-19 in peripheral and lung
487 revealed by single-cell RNA sequencing. *Cell Discov.* **6**, 1–14 (2020).
- 488 31. Dempsey, L. A. Immune dysregulation. *Nat. Immunol.* **21**, 596 (2020).
- 489 32. Parrino, J., Hotchkiss, R. S. & Bray, M. Prevention of immune cell apoptosis as potential
490 therapeutic strategy for severe infections. *Emerging Infectious Diseases* vol. 13 191–198
491 (2007).
- 492 33. Somova, L. M., Besednova, N. N. & Plekhova, N. G. Apoptosis and infectious diseases.
493 *Russ. J. Infect. Immun.* **4**, 303–318 (2015).
- 494 34. Fathi, N. & Rezaei, N. Lymphopenia in COVID-19: Therapeutic opportunities. *Cell Biol.*
495 *Int.* **44**, 1792–1797 (2020).
- 496 35. Taghiloo, S. *et al.* Apoptosis and immunophenotyping of peripheral blood lymphocytes in
497 Iranian COVID-19 patients: Clinical and laboratory characteristics. *J. Med. Virol.* **93**,
498 1589–1598 (2021).
- 499 36. Ge, Y. L. *et al.* Elevated plasma D-dimer in adult community-acquired pneumonia
500 patients is associated with an increased inflammatory reaction and lower survival. *Clin.*
501 *Lab.* **65**, 131–138 (2019).
- 502 37. Fruchter, O., Yigla, M. & Kramer, M. R. D-dimer as a prognostic biomarker for mortality
503 in chronic obstructive pulmonary disease exacerbation. *Am. J. Med. Sci.* **349**, 29–35
504 (2015).
- 505 38. Mikami, T. *et al.* Risk Factors for Mortality in Patients with COVID-19 in New York
506 City. *J. Gen. Intern. Med.* **36**, 17–26 (2021).
- 507 39. Laing, A. G. *et al.* A dynamic COVID-19 immune signature includes associations with
508 poor prognosis. *Nat. Med.* **26**, 1623–1635 (2020).
- 509 40. Leija-Martínez, J. J. *et al.* IL-17A and TNF- α as potential biomarkers for acute respiratory
510 distress syndrome and mortality in patients with obesity and COVID-19. *Med. Hypotheses*
511 **144**, 109935 (2020).
- 512 41. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in
513 Wuhan, China. *Lancet* **395**, 497–506 (2020).
- 514 42. Kang, S. *et al.* IL-6 trans-signaling induces plasminogen activator inhibitor-1 from
515 vascular endothelial cells in cytokine release syndrome. *Proc. Natl. Acad. Sci. U. S. A.*
516 **117**, 22351–22356 (2020).
- 517 43. Cron, R. Q. COVID-19 cytokine storm: targeting the appropriate cytokine. *Lancet*
518 *Rheumatol.* **0**, (2021).
- 519 44. Pacha, O., Sallman, M. A. & Evans, S. E. COVID-19: a case for inhibiting IL-17? *Nature*
520 *Reviews Immunology* vol. 20 345–346 (2020).
- 521 45. Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M. & Suliman, B. A.
522 MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17
523 cytokine profile. *Cytokine* **104**, 8–13 (2018).

- 524 46. Xie, M., Cheng, B., Ding, Y., Wang, C. & Chen, J. Correlations of IL-17 and NF- κ B gene
525 polymorphisms with susceptibility and prognosis in acute respiratory distress syndrome in
526 a Chinese population. *Biosci. Rep.* **39**, (2019).
- 527 47. Eden, G., Archinti, M., Furlan, F., Murphy, R. & Degryse, B. The urokinase receptor
528 interactome. *Curr. Pharm. Des.* **17**, 1874–1889 (2011).
- 529 48. Zuo, Y. *et al.* Plasma tissue plasminogen activator and plasminogen activator inhibitor-1
530 in hospitalized COVID-19 patients. vol. 11 1580.
- 531 49. Cesari, M., Pahor, M. & Incalzi, R. A. REVIEW: Plasminogen Activator Inhibitor-1 (PAI-
532 1): A Key Factor Linking Fibrinolysis and Age-Related Subclinical and Clinical
533 Conditions. *Cardiovasc. Ther.* **28**, e72–e91 (2010).
- 534 50. Ji, H. L., Zhao, R., Matalon, S. & Matthay, M. A. Elevated plasmin(Ogen) as a common
535 risk factor for COVID-19 susceptibility. *Physiol. Rev.* **100**, 1065–1075 (2020).
- 536 51. Matsuyama, T., Kubli, S. P., Yoshinaga, S. K., Pfeffer, K. & Mak, T. W. An aberrant
537 STAT pathway is central to COVID-19. *Cell Death and Differentiation* vol. 27 3209–
538 3225 (2020).
- 539 52. Umemura, Y. *et al.* Hematological Phenotype of COVID-19-Induced Coagulopathy: Far
540 from Typical Sepsis-Induced Coagulopathy. *J. Clin. Med.* **9**, 2875 (2020).
- 541 53. Cabrera-Garcia, D. *et al.* High levels of plasminogen activator inhibitor-1, tissue
542 plasminogen activator and fibrinogen in patients with severe COVID-19. *medRxiv*
543 2020.12.29.20248869 (2021) doi:10.1101/2020.12.29.20248869.
- 544 54. Cugno, M. *et al.* Complement activation and endothelial perturbation parallel COVID-19
545 severity and activity. *J. Autoimmun.* **116**, 102560 (2021).
- 546 55. Hemmat, N. *et al.* The roles of signaling pathways in SARS-CoV-2 infection; lessons
547 learned from SARS-CoV and MERS-CoV. *Archives of Virology* vol. 166 675–696 (2021).
- 548 56. Shirato, K. & Kizaki, T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory
549 responses via toll-like receptor 4 signaling in murine and human macrophages. *Heliyon* **7**,
550 e06187 (2021).
- 551 57. Solimani, F., Meier, K. & Ghoreschi, K. Janus kinase signaling as risk factor and
552 therapeutic target for severe SARS-CoV-2 infection. *Eur. J. Immunol.* eji.202149173
553 (2021) doi:10.1002/eji.202149173.
- 554 58. Zhang, Y. & Bliska, J. B. Role of toll-like receptor signaling in the apoptotic response of
555 macrophages to Yersinia infection. *Infect. Immun.* **71**, 1513–1519 (2003).
- 556
557